Volatility estimates for rckt remain below historical averages, aligning the stock forecast with a more controlled upside trajectory. This could appeal to investors seeking biotech exposure without excessive short-term risk. H.C. Wainwright initiated coverage of NewAmsterdam Pharma (NAMS) with a Buy rating and $48 price target. The firm believes obicetrapib, as a low-dose, oral, once-daily treatment, may emerge as the preferred lipid-lowering therapy for patients with hypercholesterolemia, as monotherapy or as a fixed-dose combination with ezetimibe. Obicetrapib has the clinical profile to be transformational for millions of patients not at Find stocks with ease across diverse datasets and filters Updated technical charts show rckt forming an ascending triangle, often interpreted as bullish by chartists. The rckt stock forecast anticipates a breakout if daily close stays above $4.90 with increasing volume and strong moving average alignment.
